News and Events

What's new and upcoming with EarlySign


Medial EarlySign’s Co-founder Ori Geva and CEO Dr. Jeremy Orr describe the company's development, from its origin as a Silicon Valley-like startup operating out of an Israeli garage, to its growth and deployment of clinical algorithmic solutions with leading health systems in both Israel and the U.S.
Today on THCB Spotlights, Matthew speaks with Jeremy Orr, CEO of Medial EarlySign. Medial EarlySign does complex algorithmic detection of elevated risk trajectories for high-burden serious diseases, and the progression towards chronic diseases such as diabetes.

Press Releases

New Study Shows EarlySign’s Machine Learning Algorithm Can Predict Which Cardiac Patients are at High-Risk Following Discharge

TEL AVIV, Israel and ROCHESTER, MN – September 4, 2019 – Medial EarlySign (, a leader in machine-learning based solutions to aid in early detection and prevention of high-burden diseases, today announced the results of new research with Mayo Clinic assessing the effectiveness of machine learning for predicting cardiac patients’ future risk trajectories following hospital discharge.

Learn More


MedCity CONVERGE brings together all sectors of the oncology ecosystem — health systems, insurers, digital health, investors, hospitals, pharma, entrepreneurs and other key stakeholders — to discover the latest innovations and the future of cancer care.

Are you looking to solve high-burden disease challenges?